US 12,290,508 B2
Methods of use for trisubstituted benzotriazole derivatives
Danielle Ulanet, Cambridge, MA (US); and Sung Eun Choe, Lexington, MA (US)
Assigned to Servier Pharmaceuticals LLC, Boston, MA (US)
Filed by Servier Pharmaceuticals LLC, Boston, MA (US)
Filed on Jun. 9, 2023, as Appl. No. 18/207,887.
Application 18/207,887 is a continuation of application No. 16/971,199, granted, now 11,717,512, previously published as PCT/US2019/018472, filed on Feb. 19, 2019.
Prior Publication US 2024/0148697 A1, May 9, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4192 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/4192 (2013.01) [A61P 35/00 (2018.01)] 5 Claims
 
1. A method of treating double hit diffuse large B cell lymphoma or triple hit diffuse large B cell lymphoma in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by the following structural formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof; wherein:
the dotted lines [ . . . ] in the ring represent an optional bond which may be present in any stable combination;
R1 is selected from hydrogen and alkyl;
R2 is -A-R4;
A is arylene or tetrasubstituted arylene; wherein the substituent is halogen;
R3 is selected from hydroxy and amino;
R4 is selected from an aryl and a heteroaryl that is optionally substituted with one or more R5;
R5 is selected from alkyl and —(CH2)nN(Ra)Rb;
Ra and Rb are independently selected from hydrogen, alkyl and —C(O)alkyl;
alternatively Ra and Rb can be taken together with the nitrogen atom to which they are attached to form a 4-6 membered heterocyclyl containing 0-2 additional heteroatoms independently selected from O and N and is optionally substituted with alkyl; and
n is an integer selected from 0 and 1.